Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213733 | 0.78 | EPHX1 (0.43) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL28694029 | 0.78 | EPHX1 (0.43) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL29384470 | 0.71 | EPHX1 (0.41) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL9800227 | 0.70 | EPHX1 (0.67) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL1570434 | 0.70 | EPHX1 (0.67) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL2343227 | 0.70 | EPHX1 (0.59) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL17205447 | 0.70 | EPHX1 (0.67) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL9800070 | 0.70 | EPHX1 (0.67) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL7362431 | 0.70 | EPHX1 (0.59) | EPHX1NOS2PSEN1PSEN2APH1B | |
| SCHEMBL13557474 | 0.70 | EPHX1 (0.67) | EPHX1NOS2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819484-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2023-11-21 | — | — | US | disclosed |
| CN-110114338-B | Retinoid derivatives having antitumor activity | 比奥吉公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11364216-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2022-06-21 | — | — | US | disclosed |
| US-20220168252-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2022-06-02 | — | — | US | disclosed |
| US-20210052530-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2021-02-25 | — | — | US | disclosed |
| US-10905668-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2021-02-02 | — | — | US | disclosed |
| EP-3519383-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | Biogem S.C. A R.L. (IT) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018060354-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S.CA.R.L. (IT) | 2018-04-05 | — | — | WO | disclosed |
| EP-3301085-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S.CA.R.L. (IT) | 2018-04-04 | — | — | EP | disclosed |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | F. HOFFMAN-LA ROCHE LTD | 2016-12-29 | — | — | US | disclosed |
| US-20040167182-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-08-26 | — | — | US | disclosed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004013130-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004000811-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1301517-A1 | THIENOPYRROLIDINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-6528653-B2 | E.g., 4,6-dihydro 4-(heterocyclic ring-methylene)thieno(2,3-b) pyrrolidin-5-one derivatives; tumor necrosis factor ) inhibitors; anticarcinogenic, -proliferative and -arthritic agents; Alzheimer's disease; cardiovascular disorders | HOFFMANN-LA ROCHE, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020028841-A1 | Thienopyrrolidinones | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | US | disclosed |
| WO-2002002567-A1 | THIENOPYRROLIDINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168252-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | RARA, RARB, RARG | EPHX1 610/4885NOS2 1249/4885PSEN1 4007/4885 |
| US-10905668-B2 | Retinoid derivatives with antitumor activity | RARA, RARB, RARG | EPHX1 610/4885NOS2 1249/4885PSEN1 4007/4885 |
| US-20040167182-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | MMP1, MMP3, MMP13 | EPHX1 354/4885NOS2 2407/4885PSEN1 960/4885 |
| US-11819484-B2 | Retinoid derivatives with antitumor activity | RARA, RARB, RARG | EPHX1 610/4885NOS2 1249/4885PSEN1 4007/4885 |
| US-20210052530-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | RARA, RARB, RARG | EPHX1 610/4885NOS2 1249/4885PSEN1 4007/4885 |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | TTR, TYMP, TPMT | EPHX1 1895/4885NOS2 3838/4885PSEN1 122/4885 |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | EPHX1 899/4885NOS2 1533/4885PSEN1 1350/4885 |
| US-11364216-B2 | Retinoid derivatives with antitumor activity | RARA, RARB, RARG | EPHX1 610/4885NOS2 1249/4885PSEN1 4007/4885 |
| US-20020028841-A1 | Thienopyrrolidinones | TNF, TYMP, TNFRSF1A | EPHX1 1193/4885NOS2 519/4885PSEN1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.